WHAT THIS STUDY ADDS?
• This study confirmed that ALB, route of administration and
concomitant administration with glucocorticoid (GLU) and proton pump
inhibitors (PPIs) are significantly associated with voriconazole trough
concentration in children with hematological malignancies.
• The population pharmacokinetics (PPK) analysis demonstrated
that the extensive metabolizer, albumin significantly affects
voriconazole clearance in children with malignant hematological disease.
• The dosing regimen based on CYP2C19 genotype and albumin
could provide a reference for individualized administration of
voriconazole in clinical practice.